# DARE (NCT04567420)

> DNA-guided Second Line Adjuvant Therapy for High Residual Risk, Estrogen Receptor Positive, HER-2 Negative Breast Cancer (DARE)

No report yet. It can be ordered.

## Registry

- Registry record: https://clinicaltrials.gov/study/NCT04567420
- Phase: PHASE2
- Status: ACTIVE_NOT_RECRUITING
- Sponsor: Criterium, Inc.
- Conditions: Breast Cancer
- Interventions: Palbociclib; Fulvestrant; Adjuvant Therapy
- Enrollment: 70
- Primary outcome: Surveillance/ctDNA screening Phase
- Primary outcome: Therapeutic Phase

## Preliminary discovery

Commentary in our index that names this trial so far. Final coverage is set when the report is built.

- YouTube: 20
- Podcasts: 11
- X threads: 9
- Bluesky threads: 4

## Order

Deep, $1,950, price fixed at order: https://www.erudio.com/contact?report=dare-nct04567420

## Free preview

POST https://www.erudio.com/api/trial-requests with {"nct_id": "NCT04567420", "email": "<work email>"}; the inbox owner confirms by the emailed link.